Drug Approval | October 04, 2021
Biocon launches Everolimus tablets in the US
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled
HTL will build, validate and operate a botulinum manufacturing facility in the US
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Subscribe To Our Newsletter & Stay Updated
